Jacques Irani

TL;DR: Even when anaesthesia-free, transrectal ultrasound-guided prostatic biopsy was felt to be only mildly uncomfortable by most patients, but 19% judged that it should be accompanied by some form of anaesthesia, local anaesthetic techniques to enhance tolerance to this type of intervention without sacrificing the advantages of the current out-patient setting should be reassessed.

TL;DR: There is a subgroup of T1G3 patients with age ≥ 70 yr, tumor size ≥ 3 cm, and concomitant CIS who have a high risk of progression and thus require aggressive treatment and should be treated more aggressively.

TL;DR: Prostatic subclinical inflammation is not associated with high urinary PSA unless associated with glandular epithelial disruption, and density of prostatic interstitial inflammatory cell infiltrate is not significantly correlated with serum PSA concentration.

TL;DR: The Association Francaise d'Urologie recommends prostate cancer screening by PSA assay (prostate specific antigen) and digital rectal examination annually between the ages of 50 and 75 years, and from the age of 45 years in men with a family or ethnic risk.

TL;DR: The PROGENSA PCA3 assay can aid in guiding biopsy decisions in predicting initial biopsy outcome, and may be indicative of prostate cancer aggressiveness.